SEC Form 4/A · accession 0001209191-18-062480
PhaseBio Pharmaceuticals Inc · PHAS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
This is an amendment (Form 4/A). It replaces an earlier filing for the same period.
Reporting owner
Jonathan P Mow
Officer — Chief Executive Officer · Director
Period of report
Dec 7, 2018
Accepted (ET)
Dec 13, 2018 · 5:04 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001169245
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Dec 7, 2018 | P | 700 | $3.89 | A | 49,399 | I | By the Mow Trust dated April 17, 2008 |
| Common StockF3,F2 | Dec 10, 2018 | P | 800 | $3.85 | A | 50,199 | I | By the Mow Trust dated April 17, 2008 |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.73 to $4.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4.
- F2The reporting person and his wife are joint trustees of the Mow Trust dated April 17, 2008 and share voting and dispositive power for such shares. The reporting person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.
- F3The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.80 to $3.90, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4.
Remarks
This Amendment is being filed to correct the number of shares purchased by the Reporting Person reported on the Form 4 filed with the Securities and Exchange Commission on December 11, 2018.